|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Cost of sales | |||||
| Excise taxes on products | |||||
| Gross profit | |||||
| Marketing, administration and research costs | |||||
| Asset impairment and exit costs, net of cash paid | |||||
| Impairment of goodwill | |||||
| Operating income | |||||
| Loss on early extinguishment of debt | |||||
| Interest and other debt expense, net | |||||
| Net periodic benefit income, excluding service cost | |||||
| (Income) losses from investments in equity securities | |||||
| Loss on Cronos-related financial instruments | |||||
| Gain on the sale of IQOS System commercialization rights | |||||
| Earnings before income taxes | |||||
| Provision for income taxes | |||||
| Net earnings | |||||
| Per share data: | |||||
| Basic earnings per share attributable to Altria (in usd per share) | |||||
| Diluted earnings per share attributable to Altria (in usd per share) | |||||
Loading...